Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids
Status:
Withdrawn
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This is a pilot study to investigate the safety and efficacy of intravitreally administered
ranibizumab (Lucentis) compared to steroid injection for the treatment of macular edema due
to chronic non-infectious uveitis. There is currently no FDA-approved therapy for this
condition, however intravitreal injection of corticosteroids, in conjunction with oral
steroids and/or immunomodulatory drug agents, has become the mainstay of therapy. Ranibizumab
is a recombinant monoclonal antibody antigen-binding fragment that neutralizes the active
forms of vascular endothelial growth factor (VEGF), which is believed to contribute to the
etiology of inflammation and neovascularization. Ranibizumab is FDA-approved for the
treatment of neovascular age-related macular degeneration.